Highlights ESMO 2024: O que de relevante tivemos em tumores gastrointestinais?

Neste vídeo, a Dr Fábio Kater comenta sobre alguns dos mais importantes estudos que foram apresentados durante a ESMO 2024

Neste vídeo, o Dr Fábio Kater faz um resumo dos estudos mais relevantes que foram apresentados sobre o manejo de tumores gastrointestinais. 

Os estudos comentados foram: 

1. Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo); bevacizumab (bev) vs active surveillance in patients (pts)with resected or ablated high-risk hepatocellular carcinoma (HCC)
2. A randomized phase III trial of perioperative chemotherapy (periop CT) with or without preoperative chemoradiotherapy (preop CRT) for resectable gastric cancer (AGITG TOPGEAR): Final results from an intergroup trial of AGITG, TROG, EORTC and CCTGLIP12
3. Transarterial chemoembolization (TACE) with or without lenvatinib (len); pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): Phase III LEAP-012 study
4. Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2
5. Neoadjuvant nivolumab (nivo) plus relatlimab (rela) in MMR-deficient colon cancer: Results of the NICHE-3 study
6. IMHOTEP Phase II trial of neoadjuvant pembrolizumab in dMMR/MSI tumors: Results of the colorectal cancer cohort
7. Total neoadjuvant treatment (TNT) with non-operative management (NOM) for proficient mismatch repair locally advanced rectal cancer (pMMR LARC): First results of NO-CUT trial 

Para saber mais, acesse o vídeo completo!